- Home
- PMEC vs RVPH Comparison
PMEC vs RVPH Comparison
Compare PMEC & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- RVPH
- Stock Information
- Founded
- PMEC 1984
- RVPH 2006
- Country
- PMEC Singapore
- RVPH United States
- Employees
- PMEC N/A
- RVPH N/A
- Industry
- PMEC
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- RVPH Health Care
- Exchange
- PMEC Nasdaq
- RVPH Nasdaq
- Market Cap
- PMEC 29.3M
- RVPH 33.4M
- IPO Year
- PMEC 2023
- RVPH N/A
- Fundamental
- Price
- PMEC $0.76
- RVPH $1.26
- Analyst Decision
- PMEC
- RVPH Strong Buy
- Analyst Count
- PMEC 0
- RVPH 4
- Target Price
- PMEC N/A
- RVPH $15.33
- AVG Volume (30 Days)
- PMEC 57.5K
- RVPH 688.9K
- Earning Date
- PMEC 12-26-2024
- RVPH 11-26-2024
- Dividend Yield
- PMEC N/A
- RVPH N/A
- EPS Growth
- PMEC N/A
- RVPH N/A
- EPS
- PMEC N/A
- RVPH N/A
- Revenue
- PMEC $72,524,000.00
- RVPH N/A
- Revenue This Year
- PMEC N/A
- RVPH N/A
- Revenue Next Year
- PMEC N/A
- RVPH N/A
- P/E Ratio
- PMEC N/A
- RVPH N/A
- Revenue Growth
- PMEC 5.07
- RVPH N/A
- 52 Week Low
- PMEC $0.49
- RVPH $0.60
- 52 Week High
- PMEC $4.15
- RVPH $5.67
- Technical
- Relative Strength Index (RSI)
- PMEC 50.46
- RVPH 55.87
- Support Level
- PMEC $0.67
- RVPH $0.88
- Resistance Level
- PMEC $0.78
- RVPH $1.22
- Average True Range (ATR)
- PMEC 0.06
- RVPH 0.14
- MACD
- PMEC -0.00
- RVPH 0.02
- Stochastic Oscillator
- PMEC 52.14
- RVPH 64.91
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.